文献速递肿瘤 PET/CT核素与放射性配体治疗神经核医学

68Ga-DOTA-FAPI-46 PET/CT用于转移性嗜铬细胞瘤再分期:与68Ga-DOTA-TATE PET/CT比较

68 Ga-DOTA-FAPI-46 PET/CT Imaging for Restaging in a Patient With Metastatic Pheochromocytoma : Comparison With 68 Ga-DOTA-TATE PET/CT.
PubMed 文献 · Clin Nucl Med · 2024-10-03

本文报道一名42岁男性转移性嗜铬细胞瘤(PHEO)患者的再分期影像,比较68Ga-DOTA-FAPI-46 PET/CT与68Ga-DOTA-TATE PET/CT的显像表现。文中提及FAP在包括PHEO在内的多种肿瘤相关成纤维细胞中过表达,68Ga标记生长抑素类似物PET在副神经节瘤诊断中表现优于123I-MIBG闪烁显像。

要点

  • 转移性嗜铬细胞瘤患者再分期中,同时行68Ga-DOTA-FAPI-46与68Ga-DOTA-TATE PET/CT显像。
  • FAP在包括嗜铬细胞瘤在内的多种肿瘤相关成纤维细胞中过表达。
  • 68Ga标记生长抑素类似物PET在副神经节瘤诊断中表现优于123I-MIBG闪烁显像。

核心结论

  • 本文报告一例42岁男性转移性嗜铬细胞瘤患者的68Ga-DOTA-FAPI-46 PET/CT与68Ga-DOTA-TATE PET/CT再分期显像表现。

研究设计与样本

  • 本文为病例报告,对象为一名42岁确诊转移性嗜铬细胞瘤的男性患者,行68Ga-DOTA-FAPI-46 PET/CT与68Ga-DOTA-TATE PET/CT再分期显像。

主要发现

  • 原文未报告两种显像的具体病灶摄取数值或对比结果。

关键数值与推荐

  • 原文未报告诊断阈值或判读标准。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Pheochromocytomas (PHEOs) are neural crest-derived tumors originating from the chromaffin cells of the adrenal medulla and were recognized as one of the subtypes of paragangliomas by the World Health Organization in 2022. 68 Ga-labeled somatostatin analog ( 68 Ga-DOTA-NOC, 68 Ga-DOTA-TOC, and 68 Ga-DOTA-TATE) PET imaging has shown significant performance compared with 123 MIBG scintigraphy in the diagnosis of paragangliomas. It is now known that fibroblast activation protein (FAP) is overexpressed by various cancer-associated fibroblasts, including PHEOs. We would like to present the findings of 68 Ga-DOTA-FAPI-46 PET/CT and 68 Ga-DOTA-TATE PET/CT imaging performed for restaging on a 42-year-old man diagnosed with metastatic PHEO.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Şahin R, Baloğlu MC, Ergül N, et al. 68 Ga-DOTA-FAPI-46 PET/CT Imaging for Restaging in a Patient With Metastatic Pheochromocytoma : Comparison With 68 Ga-DOTA-TATE PET/CT. Clin Nucl Med. 2024. PMID: 39365092. doi:10.1097/RLU.0000000000005481

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。